Korean Stem Cell Med for Sale

South Korea approves the first stem-cell medication for clinical use.

By | July 8, 2011

LEONARDINI / STOCK.XCHNG

After six years of clinical trials, the South Korean Food and Drug Administration approved a stem-cell-based treatment for commercial sale last week—making South Korea the first country where a stem cell medication has been green-lighted for clinical use. Developed by FCB-Pharmicell, a Korean biotech that specializes in stem cell drugs, Hearticellgram-AMI consists of an injection of somatic stem cells cultured from the bone marrow into the coronary arteries of patients who have suffered from acute myocardial infarction. According to the company, just one injection is enough to promote a 6 percent improvement in heart function after 6 months. However, there has been concern over a lack of independent validation of the treatment, Reuters reports, as FCB-Pharmicell’s new product is yet to be vetted by a peer review publication.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Athletes’ Microbiomes Differ from Nonathletes
  3. Mutation Linked to Longer Life Span in Men
  4. Gut Feeling
    Daily News Gut Feeling

    Sensory cells of the mouse intestine let the brain know if certain compounds are present by speaking directly to gut neurons via serotonin.

AAAS